title: [Suppression of renin-angiotensin system and cancer therapy (discussion)].
authors.forename: Kazutoku
authors.initials: K
authors.lastname: Kihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kamimura
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Isayama
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fujii
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Iino
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002927:Cimetidine / Q000008:administration & dosage; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D016898:Interferon-alpha / Q000008:administration & dosage; D008019:Life Style; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D010094:Oxonic Acid / Q000008:administration & dosage; D012084:Renin-Angiotensin System / Q000502:physiology; D005641:Tegafur / Q000008:administration & dosage; D013777:Tetrazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D052246:Cyclooxygenase 2 Inhibitors; D004338:Drug Combinations; D016898:Interferon-alpha; D013777:Tetrazoles; D003841:Deoxycytidine; D000804:Angiotensin II; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002927:Cimetidine; C081643:candesartan; D000093542:Gemcitabine